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Abstract This study aims to evaluate the relation between a
cluster of neuropsychiatric symptoms related to cholinergic
deficiency and degradation of the cortical cholinergic projec-
tions which project from the nucleus basalis of Meynert to the
cerebral cortex. An atlas of the pathway from the nucleus
basalis to the cortex (NbM cortical pathway) was constructed
using diffusion tensor imaging and tractography in 87 memo-
ry clinic patients. Structural degradation was considered to be
represented by lower fractional anisotropy (FA) and higher
mean diffusivity (MD). Neuropsychiatric symptoms were
assessed using the Neuropsychiatric Inventory. A predefined
cluster including agitation, anxiety, apathy, delusions, halluci-
nations, and irritability was labeled as the cholinergic deficien-
cy syndrome (CDS). In regression analyses, lower FA and
higher MD in the NbM cortical pathway were associated with
CDS symptoms but not with other neuropsychiatric symp-
toms. These associations were independent of cerebral atro-
phy and overall FA or MD. There was no association between
interruption of the NbM cortical pathway by white matter
hyperintensities and CDS symptoms. Cox regression sug-
gested a trend for higher mortality with lower FA in the
NbM cortical pathway may exist. These findings provide an-
atomical support for the hypothesis that degradation of the
cholinergic projections from the nucleus basalis of Meynert
may lead to a distinct clinical syndrome. Future studies could
use our results to test the utility of assessing NbM projection
integrity to identify patients who may benefit from cholinergic
treatment or with a worse prognosis.
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Introduction
The cholinergic innervation of the neocortex stems almost
exclusively from the nucleus basalis of Meynert (NbM), lo-
cated in the basal forebrain (Saper et al. 2010; Mesulam 2013;
Gratwicke et al. 2013). Atrophy of the basal forebrain cholin-
ergic system is a progressive feature in normal aging, aggra-
vated in mild cognitive impairment and pervasive from the
onset in Alzheimer’s and other dementias (Grothe et al.
2012; Teipel et al. 2011; Schliebs and Arendt 2011). Loss of
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cortical cholinergic innervation is thought to play an important
role in the development of psychiatric and behavioral symp-
toms (Pinto et al. 2011). Experimental and clinical observa-
tions have led to the hypothesis that a specific subset of neu-
ropsychiatric symptoms is susceptible to cholinergic medica-
tion (Lemstra et al. 2003; Pinto et al. 2011). This cluster of
symptoms, termed BCholinergic Deficiency Syndrome^
(CDS), was hypothesized to be evoked by impaired cortical
cholinergic stimulation, causing loss of attention, concentra-
tion, and capacity to discern stimuli, provoking clinical symp-
toms including agitation, anxiety, apathy, delusions, halluci-
nations and irritability (Lemstra et al. 2003; Pinto et al. 2011).
From the NbM in the basal forebrain, cholinergic fibers
travel towards the cortex together with other, non-cholinergic,
projections from the basal forebrain and mesencephalon
(Saper et al. 2010). These projections form a medial and lat-
eral bundle from which axons emanate and fan towards the
cortex (Mesulam 2013; Selden et al. 1998). According to the
CDS hypothesis, disruption of the cholinergic NbM projec-
tions may incite CDS symptoms, by chronically interfering
with cortical cholinergic innervation. The diversity of the
symptoms associated with the CDS, may be explained by
the different roles the reciprocal NbM projections fulfill
throughout the cerebrum by serving more fundamental roles
of detection, selection, discriminating and processing of stim-
uli (Lemstra et al. 2003; Pinto et al. 2011; Klinkenberg et al.
2011). Cholinergic stimulation of the hippocampal area seems
important for short-term information acquisition, of the amyg-
dala for anxiety regulation, and of the somatosensory areas for
stimulus discrimination (Klinkenberg et al. 2011). Disruption
of the NbM projections to the limbic system may lead to
emotional changes, to the cingulate and prefrontal cortex to
motivational and executive symptoms, and to the occipital
cortex to hallucinations (Pinto et al. 2011; Klinkenberg
et al. 2011; Liu et al. 2015). However, most likely behav-
ioral symptoms rely on synchronized activity regulation of a
wide range of neuronal networks and cannot be attributed to
dysregulation of single, clearly delimited brain regions
(Klinkenberg et al. 2011).
One cause of disruptions of the NbM projections may be
white matter hyperintensities of presumed vascular origin
(WMH), a common finding on brain magnetic resonance im-
aging (MRI) in older persons (Gouw et al. 2011; Moran et al.
2012; Debette and Markus 2010; Schmidt et al. 2011).
Pathologically, WMH are heterogeneous anomalies thought
to represent various degrees of ischemic white matter damage
(Gouw et al. 2011; Moran et al. 2012; Schmidt et al. 2011).
Their clinical correlates include cognitive and neuropsy-
chiatric symptoms (Gouw et al. 2011; Moran et al. 2012;
Debette and Markus 2010; Schmidt et al. 2011; Berlow
et al. 2010), and may be spatially dependent (Tighe et al.
2012; Mortamais et al. 2013; Bocti et al. 2005; Bohnen
et al. 2009). For example, WMH interfering with the
cholinergic NbM projections may incite symptoms of
cholinergic deficiency (Bocti et al. 2005; Bohnen et al.
2009). Although WMH severity in regions likely to con-
tain NbM projections has been associated with cognitive
impairment, accurate identification of these projections is
difficult (Bocti et al. 2005; Bohnen et al. 2009; Kim et al.
2012; Behl et al. 2007). This makes further delineation of
cholinergic brain-behavior relations problematic.
Previous studies have identified the cholinergic projections
using visual rating scales (Bocti et al. 2005; Behl et al. 2007).
Other studies have used diffusion tensor MRI to identify the
NbM and linkedNbM atrophy inMCI patients tomemory and
attentional deficits, cognitive decline and conversion to
Alzheimer’s disease (Grothe et al. 2016; Brueggen et al.
2015; Grothe et al. 2013; Teipel et al. 2011; Grothe et al.
2010). The correlates of loss of integrity to the NbM projec-
tions have been little studied, although one study was able to
reconstruct the medial branch of the pathway passing through
the cingulum using diffusion tensor MRI (Hong and Jang
2010). This study aims to assess the clinical manifestations
associated with structural degradation of the cortical NbM
projections in memory clinic patients evaluated for cognitive
impairment. The pathways containing these projections (NbM
cortical pathways) are reconstructed in vivo using probabilis-
tic tractography in diffusion weighted MRI data (Jones 2008).
White matter degradation is considered to be captured by
lowered fractional anisotropy (FA) and increased mean diffu-
sivity (MD) within the reconstructed projections (Jones et al.
2013). We hypothesized that such changes in FA and MD in
the NbM projections are associated with the clinical symp-
toms of the CDS and that WMH mediate this association
through interference with cholinergic projections. Also, since
NbM degeneration has been associated with more advanced
disease (Grothe et al. 2013), it may be a marker of a worse
prognosis. In an exploratory setting, we evaluated this possi-
bility by assessing whether NbM degeneration was associated
with increased mortality.
Material and methods
Population and clinical assessment
Participants were derived from a prospective cohort of pa-
tients referred to the memory clinic of the Amsterdam aca-
demic medical Centre for the evaluation of suspected cogni-
tive impairment. In addition to regular outpatient assessment
by a neurologist or geriatrician, they underwent a standardized
protocol including several questionnaires, neuropsychological
testing and MRI as part of the Dutch Parelsnoer neurodegen-
erative disease study (Talmon et al. 2008; Aalten et al. 2014).
Inclusion criteria for this study were the presence of cognitive
complaints, a clinical dementia rating of 0.5 or 1, a mini
Brain Imaging and Behavior
mental state examination (MMSE) score > 19 at the time of
first visit to the memory clinic, and a complete data set includ-
ing MRI and neuropsychiatric assessment.
In addition to a general physical and neurological exami-
nation, an extensive medical and social history was obtained
from patients and informants by an experienced neurolo-
gist or geriatrician. A trained research nurse administered
several questionnaires assessing clinical characteristics.
Global cognition was rated using the MMSE and the clin-
ical dementia rating scale. Neuropsychiatric symptoms were
assessed using the 12-item neuropsychiatric inventory (NPI).
A neuropsychological test battery was administered including
for mermory: the 15-word auditory verbal learning test (Brand
and Jolles 1985; Rey 1958) and the digit-span of the WAIS III
(forward and backward) (Wechsler 1997), for associative vi-
sual learning the short version of the visual association test
(Lindeboom et al. 2002), for verbal fluency: the 60 s animal
fluency test (Lezak 1995), and for information processing
speed: the 60 s letter digit substitution test (van der Elst et al.
2006), the Stroop color word test (10 × 10 items, 4 colors)
(Stroop 1935; van der Elst et al. 2008) and the trail making test
(TMT) part a and B (Reitan 1958). T-scores for these tests
were calculated according to Dutch normative data adjusted
for sex, age and education. Taking this information into ac-
count, a clinical diagnosis was made by a multidisciplinary
council consisting of experienced neuropsychiatrists, neurol-
ogists and geriatricians based on DSM-IV criteria (APA
1994). Dementia subtypes were based on standardized clini-
cal criteria for Alzheimer’s disease (NINCDS-ADRDA (APA
1994, McKhann et al. 1984), vascular dementia (NINDS-
AIREN criteria) (Roman et al. 1993), frontotemporal demen-
tia (Neary et al. 1998), and Lewy body dementia (McKeith
et al. 1996). Survival or date of death was registered at tele-
phone follow-up three years after baseline or through the
Dutch municipal personal records database. The study was
approved by the Amsterdam academic medical Centre insti-
tutional review board and all participants provided written
informed consent.
Definition of the CDS
Our main outcomes were: 1) number of symptoms of the
cholinergic deficiency syndrome (CDS), and 2) presence of
the CDS, operationalized as the presence of more than one
CDS symptom. CDS symptoms were defined as the following
items of the NPI: agitation, anxiety, apathy, delusions, hallu-
cinations and irritability (Pinto et al. 2011). Symptoms were
qualified as present if the product of the NPI symptom fre-
quency and severity score was >3 (Lyketsos et al. 2002). To
contrast CDS symptoms with any other neuropsychiatric
symptoms, the number of NPI symptoms not included into
the CDS and the presence of >1 non-CDS symptom were
identically analyzed as outcomes.
MRI acquisition
Imaging was performed on a 3.0 Tesla MRI system (Philips
Intera, Best, the Netherlands) with an 8-channel head coil.
Diffusion weighted MRI was performed by multi-slice spin
echo single shot echo-planar imaging, with TE/TR = 94/
6105 ms; four averaged volumes with diffusion sensitivities
of b = 0 s/mm2; 32 diffusion gradient directions with
b = 1000 s/mm2; 48 continuous (no inter-slice gap) slices, slice
thickness 3 mm, field of view = 229 × 229 mm2; acquisition
matrix=128×128; acquisition voxel size=1.79×1.79×3mm.
Furthermore, a gradient echo 3D FFE, T1-weighted, sagittal
sequence was used with TE/TR = 3.5/9 ms, field of
view = 256 × 232 mm2, scanning matrix = 256 × 231, flip
angle = 8°, voxel size = 1x1x1 mm. Also, a 2D FLAIR se-
quence was run, with TE/TR = 100/11,000 ms, TI = 2600 ms,
field of view = 230 × 183 mm, 48 slices of 3 mm thickness,
NSA = 2.
Data were anonymized prior to analysis. Diffusion tensor
imaging data was preprocessed using in-house developed
software written in Matlab (The MathWorks, Natick, MA),
executed on the Dutch e-Science Grid (www.biggrid.nl),
using a web interface to the e-Bioinfra gateway (Shahand
et al. 2013). Head motion and deformations induced by eddy
currents were corrected for by an affine registration of the
diffusion weighted images to the non-diffusion weighted im-
age. Gradient directions were corrected by the rotation com-
ponent of the transformation. Diffusion weighted images were
resampled isotropically and Rician noise was reduced using
adaptive noise filtering (Caan et al. 2010). Diffusion tensors
were estimated in a non-linear least squares sense. From the
tensors, FA and MD maps were computed.
Tractography
Tractography estimates the course of neuronal fiber tracts
crossing a pre-defined Bseed^ region. We performed probabi-
listic tractography with additional processing (BEDPOSTX)
for crossing fibers using Functional Software Library (FSL)
software (Jenkinson et al. 2012). From each seed voxel 5000
streamline samples were generated (step length: 0.5 mm, cur-
vature threshold: 0.2). This produced a connectivity map for
each seed region, with voxel intensity representing the relative
frequency streamline samples included that voxel (Fig. 1).
Higher intensity voxels are deemed more likely to contain
neural tracts connected to the seed region.
The cholinergic NbM projections run along two distinct
pathways: 1) the medial pathway predominantly through the
cingulate gyrus, and 2) the lateral pathway towards the tem-
poral lobe and towards posterior along the extreme capsule
(Mesulam 2013). To optimize NbM localization in each indi-
vidual, we adapted earlier protocols identifying mainly the
lateral (Teipel et al. 2011), and medial projections (Hong and
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Jang 2010). Two seed regions of interest (ROIs) were defined,
in native diffusion space, on the FA and color coded orienta-
tion maps. The first was placed on the lateral side of the NbM
(lateral ROI), the second at the genu of the anterior cingulate
gyrus (medial ROI).
To accurately place the lateral ROI on tracts originating from
the NbM, first, exploratory tractography of the region encapsu-
lating the NbM was performed. Probablistic fiber tracking was
performed from a box-shaped seed ROI based on previous
findings (Teipel et al. 2011), extending from the posterior of
the anterior commissure at themidline, 9mm anteriorly, 15mm
posteriorly, 15 mm ventrally, and laterally to the sagittal plane
at the lateral border of the amygdala. On the resulting connec-
tivity map, the lateral NbM tracts were identified as areas of
high connectivity located anteroventrally to the tracts crossing
the anterior commissure (Fig. 1b). The definitive lateral seed
ROI was placed on these tracts (Fig. 1c). This ROI extended
from medioventral, superior to the plane of the anterior com-
missure and laterally to the sagittal plane at the lateral border of
the amygdala, and only incorporated tracts appearing to origi-
nate from the NbM. From this ROI, definitive lateral fiber
tracking was performed. To restrict the reconstructions to the
cortical NbMprojections andminimize false positives, tracking
results crossing the midline, brain stem, hypothalamus, or optic
chiasm, were excluded with exclusion masks defined using the
T1-weighted scan and primary connectivity map.
For the medial ROI, we first performed exploratory
tractography of the tracts through the cingulate gyrus using
two seed ROIs placed on the cingulate gyrus in the coronal
plane, at the level of the anterior and posterior commissure.
Using the obtained connectivity map, a new seed ROI was
placed in the axial plane, on the fibers through the cingulate
gyrus, at the midline of the genu of the corpus callosum
(Fig. 1e, f: C) (Hong and Jang 2010). From this ROI, defini-
tive medial fiber tracking was performed. To minimize false
positives, three waypoint ROIs were used: two were placed on
the cingulate gyrus tract in the coronal plane above the ante-
rior and posterior commissure (Fig. 1f: A and B), the third was
the definitive lateral seed ROI (Fig. 1f: D). Only tracking
results intersecting at least one waypoint were retained.
Exclusion masks were not employed.
ROIs were identified manually by one rater according to
strict specifications to maximize reproducibility. Intra-rater
reproducibility was assessed in 10 random scans. Tracking
was performed separately for the medial and lateral ROIs
and separately in each hemisphere. Maps of the NbM cortical
Fig. 1 ROI placement for the lateral (top row) and medial (bottom row)
tracking technique. Connectivity map of the region encompassing the
NBM projected onto the T1 scan of the same patient. Voxels with a
high probability of containing fiber tracts are depicted in light yellow,
resolving into dark red as probability decreases. Top row: a Axial slice,
slightly caudal to the anterior commissure. b Detailed view of the region
of the NbM. NbM: Track identified as originating from the basal nucleus
(NbM). AC: Track identified as originating from the anterior commissure.
c Detailed view of the region of the NbM. ROI: seed ROI for definitive
fiber tracking, covering the fibers suspected to originate from the NbM.
Bottom row: d Axial slice at the middle of the genu of the corpus
callosum. e Detailed view of the cingulate gyrus at the genu of the
corpus callosum. The definitive seed ROI was placed on the tracts
identified by fiber tracking of the cingulate gyrus f Sagittal slice
through the left cingulate gyrus, A: posterior cingulate gyrus waypoint,
B: anterior cingulate gyrus waypoint, C: medial nucleus basalis of
Meynert (NbM) seed, D: lateral NbM seed (top row c), used as third
waypoint for the medial tracking technique
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pathway reconstructed from the lateral and medial ROI were
combined to form one NbM projection map for each patient.
Generation of NbM cortical pathway atlas
To avoid statistical biases introduced by individual variance in
reconstruction accuracy (Jbabdi and Johansen-Berg 2011), in-
dividual results were combined to form a population atlas of
the NbM cortical pathway, on which analyses were based. FA
volumes were non-linearly registered to standard space
(Andersson et al. 2007a, 2007b). Normalized individual track-
ing results and MD maps were warped accordingly. The pop-
ulation atlas was created by averaging the warped tracking
results. To discard spurious results, connectivity map mini-
mum intensity thresholds were arbitrarily set at 5 % of the
maximum intensity (Groppa et al. 2014; Galantucci et al.
2011), at which they showed good resemblance to anatomical
descriptions of the NbM projections (Selden et al. 1998).
Since the NbM projections fan out towards the cortex, white
matter degradation more proximal to the NbM may have a
more general disruptive effect on cortical stimulation than
more distal degradation. To evaluate this possibility, we divid-
ed the reconstructed NbM pathway into proximal, intermedi-
ate, and distal regions. For this purpose, a ROI drawn around
the NbM was expanded over the pathway in steps of 1 voxel,
until its overlap was complete. The proximal, intermediate and
distal segments were based upon tertiles of the number of
steps needed to cover the entire pathway.
Brain structure parameters
For each patient, mean FA andMD in the whole, the proximal,
intermediate, and distal segments of the NbM pathway were
calculated. Whole brain mean FA and MD (overall FA and
overall MD) were computed to allow comparison with global
FA and MD effects. Using Slicer 3D (Fedorov et al. 2012),
WMH were segmented on FLAIR scans corrected for bias
fields using the n4ITK filter. WMHwere segmented manually
with a minimumWMH intensity threshold, set at the intensity
of the most intense voxels in the insular cortex, where cortical
intensity was generally the highest. This was done to optimize
reproducibility and consistency between scans (Olsson et al.
2013). This process was repeated for 10 random scans to test
for intra-rater reliability. WMH maps were normalized to the
NbM atlas and then used to calculate patients’ total WMH
volume and WMH volume overlapping with the NbM path-
way. We operationalized cerebral atrophy as 1 minus the ratio
of total brain volume to intra cranial volume. Intra cranial and
total brain volumes were obtained using Statistical Parametric
Mapping (SPM) 8 on individual T1 scans (Ashburner 2012).
All calculations were performed using Functional Software
Library (FSL) software (Jenkinson et al. 2012; Woolrich
et al. 2009).
Statistical analysis
Statistical analyses were performed using SPSS 21 (IBM
corp., Armonk, NY). Intra-rater reproducibility was assessed
using the Sorensen-Dice Similarity Index: twice the volume of
overlap (Vo) between two reconstructions divided by the total
volume (V1 + V2) of those reconstructions (2*Vo/(V1 + V2))
(Sørensen 1948; Dice 1945). Differences between groups
were assessed using student t-, chi square and Mann-
Whitney U tests, where appropriate. To best fit the distribution
of the number of symptoms per patient, Poisson linear regres-
sion was used to analyze the relation between mean FA and
MD values and the total number of symptoms of the CDS.
Binary logistic regression was used to assess the relation be-
tween mean FA and MD and the presence of CDS, defined as
>1 CDS symptom. For comparison, the same models were
used to assess the relation between mean FA and MD and
the non-CDS symptoms. Models with FA based predictors
were adjusted for cerebral atrophy and overall mean FA.
Models with MD based predictors were adjusted for cerebral
atrophy and overall mean MD. Poisson linear regression and
binary logistic regression were also used to assess the associ-
ation of WMH overlap with the number of CDS symptoms
and the presence of the CDS respectively. In an exploratory
setting, the mortality hazard was assessed using Cox propor-
tional hazard models with standardized FA or MD as predic-
tor, adjusted for cerebral atrophy and respectively for overall
FA or MD. Also, subgroup analyses were performed regard-
ing number of CDS symptoms in patients with and without a
diagnosis of dementia. In addition, analyses were performed
in which age, MMSE-score and use of medication potentially
interfering with the frequency of NPI neuropsychiatric symp-
toms were also included in the adjusted model, next to cere-
bral atrophy and overall FA or MD. Potentially interfering
medication comprised anticholinergics, antidepressants, neu-
roleptics, and any medication documented to cause any of the
NPI neuropsychiatric symptoms in ≥1 % of users. Finally,
exploratory analyses were performed assessing the relation
between mean NbM FA and MD values and cerebral atrophy
andMMSE score. These analyses were restricted to the largest
diagnostic subgroup, patients with Alzheimer’s disease, since
results would likely be confounded by the diagnosis.
Results
Clinical characteristics
Between March 2010 and August 2012, 110 patients with
cognitive complaints were screened for eligibility. For 91 pa-
tients diffusion weighted imaging was available and of suffi-
cient quality for tractography. A complete examination includ-
ing the NPI was available for 87 of these patients, fulfilling
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our inclusion criteria. Screened patients with incomplete
data (n = 23) did not differ significantly from included
patients (Supplementary Table 1). Of the 87 included pa-
tients, 39 (45 %) were at the time of assessment diagnosed
with possible or probable Alzheimer’s disease, 6 (7 %)
with probable vascular dementia, 6 (7 %) with another type
of dementia (4 frontotemporal dementia, 1 Parkinson’s dis-
ease dementia and 1 cortico basal degeneration), 26 (30 %)
with mild cognitive impairment, and 10 (12 %) with sub-
jective cognitive complaints. Survival data were available
for 86 patients, one patient lost to follow-up due to emigration.
Median follow-up time was 36 months (IQR: 34–36).
During follow-up 13 patients died (median survival time:
21 months, IQR: 13–30). An overview of the neuropsycho-
logical test results per diagnostic category is provided in
Supplementary Table 2.
Patient characteristics and a summary of the NPI re-
sults are listed for the patients with CDS (n = 29) versus
those without in Table 1. Of the 29 CDS patients, 17 (59 %)
were diagnosed with possible or probable Alzheimer’s
disease, 7 (24 %) with mild cognitive impairment, 1
(3 %) with vascular dementia, 1 (3 %) with subjective
cognitive complaints and 3 (10 %) with another type of
dementia. Patients with CDS had a significantly higher
NPI score than patients without CDS (median: 27, IQR:
24–42 vs. median: 3.5, IQR: 0–9; p < 0.001), and more
non-CDS symptoms on the NPI (median 4, IQR: 3–5 vs.
median 0, IQR: 0–1, p < 0.001). There were no signifi-
cant differences regarding age, gender, MMSE score,
acetylcholinesterase inhibitor use, cerebral atrophy and
WMH volume.
NbM cortical pathway reconstruction and WMH
segmentation
Tracking results proved reproducible with an average similar-
ity index of 0.84. Reproducibility of WMH segmentation was
also good with an average similarity index of 0.86. The atlas
generated by combining the tracking results of all patients is
depicted in Fig. 2. A 3D reconstruction of the atlas with color-
coding of the separate reconstructions from the lateral and
medial ROIs and their overlap is shown in Fig. 3. The proxi-
mal, intermediate and distal divisions of the NbM cortical
pathway are shown in Supplementary Fig. 1. A standardized
version of the atlas is available to view and download online.
CDS symptoms and cholinergic projections
Results of analyses of CDS symptoms in relation to of FA and
MD in the NbM cortical pathway are listed in Table 2. Lower
FAvalues and higher MD values in the NbM cortical pathway
were associated with more CDS symptoms, specifically in the
proximal and the intermediate parts. These associations
remained significant when adjusted for cerebral atrophy and
overall FA or MD. Lower overall FAwas not associated with
more CDS symptoms.
Higher overall MD was associated with more CDS symp-
toms but less strongly than MD in the NbM cortical pathway.
Analyses with >1 symptom of CDS as outcome yielded similar
results, with slightly weaker correlations. As a control condi-
tion, the same analyses with the number of non-CDS symp-
toms and >1 non-CDS symptom as outcomes did not reveal
any significant associations (Supplementary Table 3 I-II).
Table 1 General characteristics
for the whole study population
(Total), patients with cholinergic
deficiency syndrome (CDS) de-
fined as >1 CDS symptom and
patients without CDS. Symptoms
were measured using the 12-
symptom Neuropsychiatric
Inventory (NPI). CDS symptoms
comprised agitation, anxiety, apa-








Age (IQR) 79 (71–83) 80 (74–86) 78 (70–83)
Female, n (%) 46 (53 %) 17 (59 %) 29 (50 %)
MMSE Score, m (IQR) 25 (22–27) 25 (22–26) 25 (23–27)
Acetylcholinesterase inhibitor use 2 (2 %) 1 (3 %) 1 (2 %)
NPI score 9 (1–24) 27 (24–42) (0–9)**
# NPI symptoms, m (IQR) 1 (0–3) 4 (3–5) 0 (0–1)**
> 1 CDS symptom, n (%) 29 (33 %) 29 (100 %) 0 (0 %)**
# CDS symptoms, m (IQR) 0 (0–2) 2 (2–3) 0 (0–0)**
> 1 non-CDS symptom, n (%) 15 (17 %) 12 (41 %) 3 (5 %)**
# non-CDS symptoms, m (IQR) 0 (0–1) 1 (1–2) 0 (0–1)**
Cerebral atrophy 45 % (5 %) 45 % (6 %) 44 % (4 %)
WMH volume (ml) 9.9 (5.7–15.9) 11.1 (7.9–14.9) 9.2 (4.9–16.0)
Means and standard deviations unless stated otherwise. Asterisks denote significant differences of CDS vs no
CDS
WMH white matter hyperintensity
*p<0.05, **p<0.001
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Results of analyses regarding CDS symptoms and FA and
MD for the reconstructions from the medial and lateral seed
ROI separately were similar (Table 2). The association of CDS
symptoms with lower FA and higher MD were found in both
the lateral and the medial seed ROI based reconstructions.
Exploratory analyses for the number of CDS symptoms in
dementia diagnosis subgroups showed results similar to those
of the main analyses, as did exploratory analyses with addi-
tional adjustment for age, sex and medication potentially in-
terfering with the number of CDS symptoms (Supplementary
Table 4 I-III). In the exploratory analyses regarding cerebral
atrophy andMMSE score, we found a strong relation of lower
FA and higher MD values in the NbM and greater cerebral
atrophy in Alzheimer’s disease patients, not present for overall
FA and MD (Supplementary Table 4 IV). We found no rela-
tion between FA and MD values and MMSE score in patients
with Alzheimer’s disease (Supplementary Table 4 V).
CDS symptoms and WMH
Results of regression analyses assessing the relation between
the number of CDS symptoms and the amount ofWMH over-
lap with the NbM-cortical pathway are listed in Table 3. We
found no association betweenWMH volume in the NbM cor-
tical pathway and the number of CDS symptoms. There was
also no association between total WMH volume and the
number of CDS symptoms. Results of the binary logistic anal-
yses with the same predictors and the presence of the CDS
were consistent.
NbM cortical pathway degradation and mortality
Results of Cox proportional hazard analyses with the standard-
ized FA and MD are shown in Supplementary Table 4 VI.
Lower FA in the NbM cortical pathway, particularly in the
proximal and distal segments, was associated with a two-third
higher mortality hazard per standard deviation, in contrast to
overall FA. After adjustment for cerebral atrophy and overall
brain FA, these hazard ratios were no longer significant al-
though the effect sizes remained similar. The association be-
tween the FA in the proximal NbM cortical pathway and in-
creased mortality is further illustrated in Fig. 4. Higher MD in
the NbM cortical pathway was also associated with higher
mortality, although hazard ratios were comparable to those of
the overall MD. Consequently, these associations disappeared
when adjusted for cerebral atrophy and overall MD.
Discussion
Our study shows that degradation of the NbM cortical projec-
tion pathway, as indicated by lower mean FA and higher MD
Fig. 2 Tracking results.
Combined population atlas of the
nucleus basalis of Meynert
(NbM) cortical pathway,
projected over a normal space T1
scan. Colors represent probability
map intensity ranging from 0 to
30 %. The mean fractional an-
isotropy and mean diffusivity was
analysed in the regions overlap-
ping with the atlas thresholded at
5 %. Top row: sagittal slices from
medial (left) to lateral (right).
Middle row: axial slices from
dorsal (left) to ventral (right).
Bottom row: coronal slices from
anterior (left) to posterior (right)
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values, is significantly correlated with clinical symptoms of
cholinergic deficiency in patients presenting to a memory clin-
ic. These CDS symptoms were represented by NPI domains
for agitation, anxiety, apathy, delusions, hallucinations, and
irritability, and considered present when exceeding a frequen-
cy by severity domain score > 3. The relation between CDS
symptoms and NbM degeneration is independent of cerebral
atrophy and whole brain FA andMDvalues. The correlation is
particularly strong in the regions proximal to the NbM. The
association is specific to symptoms of the CDS compared to
other neuropsychiatric symptoms and specific to degradation
of this pathway compared to overall structural degradation in
the brain. We did not find any association of CDS symptoms
with WMH volume in the NbM cortical pathway, nor with
WMH volume in general.
Our findings are consistent with the hypothesis that disrup-
tions of the cholinergic NbM projections may evoke cortical
cholinergic deficiency and CDS symptoms (Lemstra et al.
2003; Pinto et al. 2011). However, we cannot discern whether
the CDS can be attributed specifically to degradation of the
cholinergic NbM projections, since tractography cannot dif-
ferentiate between these and other non-cholinergic projections
in the same pathway. These non-cholinergic projections
largely originate from themidbrainmonoamine neuron nuclei,
posterior hypothalamus and basal forebrain, and make up the
majority of the pathway between the NbM and the cortex
(Saper et al. 2010; 2005). Projections in this pathway are in-
volved in regulating wakefulness, motivation, reward seeking,
and related functions (Saper et al. 2010; Mahler et al. 2014;
Larson-Prior et al. 2014). Arguably, dysfunction of many of
these projections could induce neuropsychiatric symptoms,
including those of the CDS. However, other findings relate
CDS symptoms to deficiency of the cholinergic NbM projec-
tions. CDS symptoms are particularly susceptible to choliner-
gic treatment (Lemstra et al. 2003; Pinto et al. 2011). The
fundamental CDS features, disturbed attention and stimulus
processing, have been linked to deficiencies in cortical cho-
linergic stimulation (Lemstra et al. 2003; Pinto et al. 2011;
Saper et al. 2010; Gratwicke et al. 2013), which is derived
almost exclusively from the NbM (Mesulam 2013). Finally,
degradation of the NbM has been linked to disturbances in
attention and stimulus processing (Lemstra et al. 2003; Pinto
et al. 2011; Gratwicke et al. 2013). This suggests CDS symp-
toms in particular are associated with degradation of the cho-
linergic NbM projections.
That proximal disruptions of the NbM projections have
more impact on cortical cholinergic activity concurs with pre-
vious findings (Teipel et al. 2011; Bocti et al. 2005; Bohnen
et al. 2009). Possibly, these have a more general effect, by
disrupting cholinergic fibers before they spread throughout
the brain more distally (Teipel et al. 2011; Selden et al.
1998; Bohnen et al. 2009). Alternatively, as the distal projec-
tions fan out (Selden et al. 1998), inter individual anatomical
variation may become too large to accurately capture in an
atlas model.
In addition to the cross-sectional association with neuro-
psychiatric symptoms, our results suggest that degradation of
the NbM cortical projections may be associated with an in-
creased risk of mortality during three year follow-up. This
might mean that NbM degeneration is associated with a worse
prognosis and possibly a marker of more advanced disease.
However, the relation between NbM projection integrity and
mortality in our study was only a trend, since it was not sig-
nificant after adjustment, and was based on exploratory anal-
yses in a relatively small study population with a limited num-
ber of events.
Our results do not support our hypothesis that structural
damage to the NbM projections byWMH leads to CDS symp-
toms. Other studies have associated WMH in general with
neuropsychiatric symptoms (Berlow et al. 2010; Kee Hyung
Park et al. 2011). Furthermore, WMH in the proximal NbM
projections have been linked to worse executive functioning
and increased dementia severity, supposedly through cholin-
ergic impairment (Bocti et al. 2005; Bohnen et al. 2009; Behl
et al. 2007). Finally, lesions within the NbM projections have
been associated with visuospatial attention disorders, which
Fig. 3 Tracking results. 3D view of the nucleus basalis of Meynert
(NbM) cortical pathway reconstructions thresholded at 5 % with colours
depicting the contribution of the projections from the medial and lateral
seed ROI separately. Blue: contribution of projections from the medial
seed ROI. Red: contribution of projections from the lateral seed ROI.
Yellow: overlap between the projections from the medial and lateral seed
ROIs. Top row: 3D brain depicting the viewing angle of the middle row
(not to scale). Middle row: lateral view of the 3D reconstruction at an
angle of 90, 45 and 20 degrees from the frontal view. Bottom row:
craniocaudal view of the 3D reconstruction depicted in the middle row
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play an important role in the CDS (Lemstra et al. 2003;
Swartz et al. 2003). As an explanation, the relation between
WMH and symptoms of cholinergic deficiency may be spe-
cific to the type of dementia. Cortical cholinergic deficiency
in vascular dementia may depend on strategic lesions in the
NbM cholinergic projections, although many Alzheimer’s
disease patients also have cerebrovascular pathology, the
effect of lesions in the NbM projections may be relatively
small since NbM function is already impaired by primary
degeneration of the NbM, which occurs from the earliest
stages in Alzheimer’s disease (Kim et al. 2013, Grothe
et al. 2012). The majority of dementia patients in our
study population have Alzheimer’s disease. The number
of vascular dementia patients in our sample was too small
to test this hypothesis. Also, methodological differences
may play a role, other studies most often employing vi-
sual rating scales to assess the impact of WMH in the
NbM projections (Bocti et al. 2005; Bohnen et al. 2009;
Fukui et al. 2006; Kim et al. 2012; Behl et al. 2007).
Finally, although morphological studies have shown that
the cholinergic fibers within WMH are often severed
(Roman and Kalaria 2006), it is possible that WMH do
not functionally disrupt cholinergic fiber integrity enough
to impact cholinergic innervation.
Table 2 Results of Poisson linear
regression of total number of
cholinergic deficiency syndrome
(CDS) symptoms predicted by the
fractional anisotropy (FA) and
mean diffusivity (MD) in the
listed regions, and binary logistic
regression of >1 symptom of the
CDS predicted by the fractional
anisotropy (FA) and mean diffu-
sivity (MD) in the listed regions.
NbM: total nucleus basalis of
Meynert (NbM) cortical pathway,
Proximal: proximal part only,
Intermediate: intermediate part
only, Distal: distal part only. NbM
medial and lateral ROI projec-
tions: cortical pathway from the
lateral and medial seed ROI
separately
number of CDS symptoms
model 1 (unadjusted) model 2 (adjusted)*
beta 95 % CI p beta 95 % CI P
FA NbM -0.24 -0.45 -0.03 0.02 -0.22 -0.44 0.00 0.05
- Proximal -0.26 -0.46 -0.06 0.01 -0.24 -0.45 -0.03 0.03
- Intermediate -0.27 -0.46 -0.07 0.01 -0.28 -0.48 -0.07 0.01
- Distal -0.15 -0.36 0.05 0.14 -0.14 -0.37 0.09 0.22
NbM medial ROI projections -0.21 -0.40 -0.13 0.04 -0.21 -0.43 0.00 0.05
NbM lateral ROI projections -0.24 -0.44 -0.04 0.02 -0.23 -0.45 -0.02 0.03
Whole brain (reference) 0.09 -0.12 0.30 0.39 0.00 -0.24 0.24 0.99
MD NbM 0.34 0.14 0.53 0.00 0.32 0.01 0.63 0.05
- Proximal 0.29 0.12 0.46 0.00 0.28 0.01 0.55 0.04
- Intermediate 0.35 0.16 0.53 0.00 0.30 0.06 0.55 0.02
- Distal 0.23 0.05 0.41 0.01 0.16 -0.05 0.38 0.14
NbM medial ROI projections 0.23 0.08 0.38 0.00 0.23 0.02 0.43 0.03
NbM lateral ROI projections 0.33 0.14 0.52 0.00 0.32 0.02 0.62 0.04
Whole brain (reference) 0.20 0.03 0.37 0.02 0.21 0.04 0.38 0.02
> 1 symptom of CDS
model 1 (unadjusted) model 2 (adjusted)*
OR 95 % CI p OR 95 % CI P
FA NbM 0.63 0.39 1.01 0.06 0.63 0.38 1.03 0.06
-Proximal 0.62 0.39 0.99 0.05 0.62 0.38 1.00 0.05
-Intermediate 0.55 0.33 0.92 0.02 0.55 0.33 0.92 0.02
-Distal 0.75 0.47 1.19 0.22 0.75 0.46 1.20 0.22
NbM medial ROI projections 0.64 0.39 1.05 0.08 0.64 0.39 1.04 0.07
NbM lateral ROI projections 0.60 0.37 0.96 0.04 0.63 0.39 1.02 0.06
Whole brain (reference) 1.04 0.67 1.63 0.85 0.95 0.56 1.62 0.85
MD NbM 1.79 1.10 2.91 0.02 2.05 0.96 4.38 0.06
-Proximal 1.86 1.13 3.05 0.02 2.17 1.03 4.55 0.04
-Intermediate 1.82 1.13 2.93 0.01 1.84 0.99 3.43 0.05
-Distal 1.56 0.97 2.51 0.07 1.41 0.84 2.39 0.20
NbM medial ROI projections 1.72 1.01 2.93 0.05 1.78 0.95 3.32 0.07
NbM lateral ROI projections 1.78 1.10 2.88 0.02 1.98 0.95 4.14 0.07
Whole brain (reference) 1.39 0.88 2.19 0.16 1.4 0.89 2.22 0.15
*Corrected for cerebral atrophy and whole brain FA for FA based predictors and whole brain MD for MD based
predictors
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This study has some limitations. Although we defined the
CDS symptoms based on previously proposed clinical char-
acteristics (Lemstra et al. 2003; Pinto et al. 2011), no formal
clinical criteria exist. The CDS and its composite symptoms
are still a putative concept and need validation. Our
operationalization of the CDS as having more than 1 CDS
symptoms was arbitrary, we therefore made the number of
CDS symptoms the main focus in our interpretations of the
analyses. The total number of CDS cases was relatively small
(n = 29), limiting the number of covariates in our regression
models. This limitation is stronger in the comparison with
patients with >1 non-CDS symptom (n = 15), possibly
allowing for a type II error. Similarly, our study population
may have been too small to detect a relation between WMH
volume and CDS symptoms. Relatively small study size may
also have affected our exploratory survival analyses, which
were based on 13 events for the whole population. Finally,
the small study size undermined our capacity to perform ex-
ploratory analyses regarding to which degree individual neu-
ropsychiatric symptoms were associated with loss of integrity
to the projections of the NbM. Our study is focused on a
sample with almost no use of acetylcholinesterase inhibitors
(only 2 participants), which left us unable to investigate their
effect on the relation between NbM pathway degeneration and
the CDS. By restricting our analyses to a literature based
predefined cluster of symptoms we aimed to avoid spurious
results. However, the limitation of this approach is that our
operationalization of CDS symptoms may be incomplete or
include symptoms which are not mediated by dysfunction
of the cholinergic projections from the NbM. Next to
small in size, the study population is also heterogeneous
in age, medication use and diagnoses underlying partici-
pants’ cognitive complaints. Exploratory analyses in pa-
tients with and without dementia and adjusted for age and
medication use however gave similar results regarding the
relation between NbM projection integrity and CDS
symptoms. Regarding tracking methodology, it could be
argued that combining reconstructions from two separate
seed ROIs predominantly increases the number of false posi-
tive results. However, our reconstructions of the NbM path-
ways are consistent with morphological descriptions based on
meticulous anatomical and neuropathological studies (Fig. 2)
(Teipel et al. 2011; Selden et al. 1998). Since both seed ROIs
contributed valid and unique parts to the overall reconstruc-
tion (Fig. 3), their combination optimized our tracking results.
Another concern may be that the exact location of the seed
ROI was not fully standardized but rather identified per pa-
tient. We employed this method to allow for the tailoring of
the ROI to the likely NbM location, taking into account inter
individual anatomical variation and distortion by regional ce-
rebral atrophy (Zaborszky et al. 2008). The good reproducibil-
ity of the tracking results supports the use of this approach.
Our findings show that the clinically defined Cholinergic
Deficiency Syndrome has a functional neuroanatomical
correlate that can be assessed in vivo using structural
MRI. They support the hypothesis that damage to the
integrity of the cholinergic NbM projections may provoke
the specific cluster CDS symptoms (Lemstra et al. 2003;
Pinto et al. 2011). Our results are relevant for research
into the role of the NbM projections in the development
Table 3. Results of Poisson linear regression of total number of
cholinergic deficiency syndrome (CDS) symptoms predicted by the over-
lap between white matter hyperintensities (WMH) and the listed regions,
and binary logistic regression of the presence of >1 symptom of the
cholinergic deficiency syndrome (CDS) predicted by the overlap between
white matter hyperintensities (WMH) and the listed regions
number of CDS symptoms
beta 95 % CI p
WMH NbM overlap volume 0.09 -0.10 0.27 0.36
-Proximal 0.12 -0.06 0.29 0.19
-Intermediate 0.07 -0.11 0.25 0.46
-Distal 0.05 -0.14 0.25 0.59
Total volume (reference) 0.08 -0.11 0.26 0.41
>1 symptom of CDS
OR 95 % CI p
WMH NbM overlap volume 0.81 0.40 1.66 0.57
-Proximal 0.86 0.45 1.65 0.65
-Intermediate 0.68 0.24 1.94 0.47
-Distal 0.87 0.47 1.61 0.67
Total volume (reference) 0.76 0.34 1.69 0.50
NbM total nucleus basalis of Meynert (NbM) cortical pathway, Proximal
proximal part only, Intermediate intermediate part only, Distal distal part
only, Total volume total brain WMH volume
Fig. 4 Survival curve high vs. low fractional anisotropy. Patients
dichotomized according to high and low mean fractional anisotropy
(FA) values in the proximal part of the nucleus basalis of Meynert
(NbM) cortical pathway. For mortality, one standard deviation higher
mean FA in the proximal NbM cortical pathway was associated with a
hazard ratio of 0.57 (95%CI: 0.34–0.94) (Table 5)
Brain Imaging and Behavior
of cognitive and behavioral deficits. Other studies of
brain-behavior relations can easily employ our developed
atlas of the NbM cortical pathways. Studies in larger co-
horts with longer follow-up may be able to substantiate
the supposed trend for increased mortality with loss of
NbM projection integrity. Others may use our atlas to
study whether measures of NbM integrity could be useful
for identification of memory clinic patients likely to ben-
efit from cholinergic medication, NbM deep brain stimu-
lation, or with a worse prognosis (Brousseau et al. 2007;
Pinto et al. 2011; Grothe et al. 2010; Van Beek and Claassen
2011; Herholz et al. 2008). Our method of exploratory
tractography may be helpful to researchers looking to identify
projections from anatomically ill-defined regions, particularly
those with large inter subject-variability or sensitive to distor-
tion by cerebral atrophy. Finally, our results show how state-
of-the-art neuroimaging techniques can be instrumental in
uncovering brain-behavior relations, combining both clinical
and neuroscientific relevance.
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